Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. (GBT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GBT · as of Mar 31, 2024
Ownership Breakdown
1
Institutional Holders
$68
Total Inst. Value
—
Shares Outstanding
1
13F Shares Held
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GBT largest shareholders · institutional ownership
Q1 2024 · SEC 13F
Showing top 1 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
HUNTINGTON NATIONAL BANK pharmaceutical preparations | 1 | 0.00% | 0.00% | $68,000 | May 3, 2024 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2024 vs prior quarter
Q1 2024
0
Increased
+0 shares0
New Positions
first time holders0
Decreased
−0 shares0
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
+0
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GBT insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
18
Sell transactions
0.11
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
PERRY MARK L director | Oct 5, 2022 | D-Return | 5,600 | — | — | 0 | Form 4 ↗ |
PATRICK DEVAL L director | Oct 5, 2022 | D-Return | 5,600 | — | — | 0 | Form 4 ↗ |
Morrison Scott W director | Oct 5, 2022 | D-Return | 5,600 | — | — | 0 | Form 4 ↗ |
Thompson Alexis A. director | Oct 5, 2022 | D-Return | 3,600 | — | — | 0 | Form 4 ↗ |
YARNO WENDY L director | Oct 5, 2022 | D-Return | 30,000 | — | — | 0 | Form 4 ↗ |
Pizzo Philip A. director | Oct 5, 2022 | D-Return | 7,500 | — | — | 0 | Form 4 ↗ |
Svoronos Dawn director | Oct 5, 2022 | D-Return | 5,600 | — | — | 0 | Form 4 ↗ |
PIERCE GLENN director | Oct 5, 2022 | D-Return | 5,600 | — | — | 0 | Form 4 ↗ |
Smith-Whitley Kim See Remarks | Oct 5, 2022 | D-Return | 18,120 | — | — | 0 | Form 4 ↗ |
JOHNSON DAVID LEE Chief Commercial Officer | Sep 28, 2022 | Gift | 22,000 | — | — | 34.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Global Blood Therapeutics, Inc. (GBT) is primarily owned by institutional investors, who hold approximately — of total shares outstanding. Company insiders own approximately —, while retail and public investors account for the remaining —.
The largest institutional shareholder of Global Blood Therapeutics, Inc. is HUNTINGTON NATIONAL BANK, holding approximately 1 shares — equal to — of outstanding shares — as of March 31, 2024.
A total of 1 institutional investors currently hold GBT stock, with a combined institutional value of approximately $68 as of the most recent 13F filing period.
Frequently asked questions
GBT ownershipGlobal Blood Therapeutics, Inc. (GBT) is primarily owned by institutional investors, who hold approximately — of shares. The largest shareholder is HUNTINGTON NATIONAL BANK with a — stake. Company insiders hold —. Data sourced from SEC Form 13F as of March 31, 2024.